ABOUT UPSTREAM: Upstream Biosciences Inc. is a biotechnology company, founded in 2004. We discover, develop, and license genetic based diagnostics for cancer susceptibility and drug response. Our proprietary data mining pipeline enables us to locate and analyze genetic variations in the regions of DNA 'upstream' of the gene, the 'gene switches,' which control the quantities and timing of expression of the genes and proteins important to disease and drug response.
Our initial candidate genetic predisposition markers are targeted against liver, prostate, ovarian and thyroid cancer with a market potential of over one billion dollars and can complement existing detection tests.
Upstream's proprietary data mining pipeline and assay generate candidate genetic biomarkers.
- Upstream Biosciences Inc. discovers and develops biomarkers to the end of validation then licenses them out to strategic partners for commercialization. We currently have four (4) candidate markers in the disease areas of liver cancer, prostate cancer, ovarian cancer and thyroid cancer.
- Upstream's diagnostic products will supplement existing cancer diagnostics tests to enhance the accuracy of early detection of cancer. Our drug response tests will allow doctors to determine if a patient will benefit or be harmed by a drug.
- Upstream's leading products are UBLC - 1001, a genetic marker for liver cancer susceptibility, UBPC - 1001, a genetic marker for prostate cancer susceptibility, UBOC - 1001, a genetic marker for ovarian cancer, and UBTC - 1001, a genetic marker for thyroid cancer.
A study released on April 27, 2006 by Kalorama Information, The Worldwide Market for In Vitro Diagnostic Tests says "World In Vitro Diagnostics Market Set to Exceed $44 Billion by 2010." According to the study, "Advances in human genomics, bioinformatics, miniaturization, and microelectronics - often blended with IT and computer technology - have led to a rapid growth spurt in the market for in vitro diagnostic tests, with worldwide sales expected to surpass $44.5 billion by 2010."
Upstream Biosciences Inc.
Genome Sciences Center
#100 - 570 West 7th Avenue
Vancouver B.C. V5Z 4S6
President & Director: Dexster Smith
CEO & Director: Joel Bellenson
CFO: Tim Fernback
Secretary, Treasurer & Director: Steve Bajic